Guilherme Safioti is a specialist in Respiratory Medicine and Global Medical Director at Teva Pharmaceuticals.
For the past 4 years he’s been working in Teva Pharmaceutical’s Digital Respiratory program, together with a large cross-function team, including device and software engineers, besides drug development functions. This program has led to the FDA-approval of the world’s first two integrated electronic inhaler devices, ProAir and AirDuo Digihaler. The fully integrated sensors measure flow rate and provides objective information about the frequency and quality of inhalation via a mobile app, empowering the patients to take an active role in their health management.
Guilherme is also designing and running clinical trials to test the effectiveness of this digital therapeutics solution to improve outcomes for asthma and COPD patients, as well as studies to develop machine-learning algorithms to predict exacerbations based on real-life usage data from the Digihaler.